Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.

Omalizumab (0.1, 0.5, 1.0, 2.0 μg/mL) has a direct effect on the B cells and can reduce the number of membrane IgE+ cells present in IL-4 plus anti-CD40 treated B cell cultures. Omalizumab alone has no effect on the viable cell number.
Omalizumab (1 μg/mL; 3, 7 days) reduces IL-6 secretion in human B cells. Omalizumab does not induce apoptosis in human B cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Omalizumab (10 mg/kg/day; ip; on day 8 to 42) increases IgE levels in human PBMC-engrafted severe combined immunodeficiency (huSCID) mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Omalizumab (10 mg/kg/day; ip; on day 8 to 42) increases IgE levels in human PBMC-engrafted severe combined immunodeficiency (huSCID) mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Peipei Liu, et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. 2020 Nov 27;11:596908.  [Content Brief]

  . Seung Y Chu, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012 Apr;129(4):1102-15.  [Content Brief]

  . Marcia A Chan, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3(1):29.  [Content Brief]